StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Zevra Therapeutics's price to sales ratio was 5.2× on Nov 11, 2026, against 5.6× a year earlier. Over the last 5 years it ranged from 4.5× to 21.9×, with a median of 10.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.2×−0.8
2025Dec 31, 20256.0×−12.2
2024Dec 31, 202418.1×+3.8
2023Dec 29, 202314.3×−0.5
2022Dec 30, 202214.8×+4.0
2021Dec 31, 202110.8×+6.7
2020Dec 31, 20204.1×–

More Zevra Therapeutics figures

See a number that looks wrong?